+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Psychedelic Drugs Market 2030 by Source, Drug Type, Distribution Channel and Region - Partner & Customer Ecosystem Competitive Index & Regional Footprints

  • PDF Icon

    Report

  • 180 Pages
  • August 2023
  • Region: Global
  • MarketDigits
  • ID: 5923592
The Psychedelic Drugs Market size is estimated to grow from USD 3.6 Billion in 2022 to reach USD 4.6 Billion by 2030, growing at a CAGR of 13.5% during the forecast period from 2023 to 2030.

Major players Psychedelic Drugs Market include: Jazz Pharmaceuticals, Inc., Janssen Pharmaceuticals, Pfizer Inc., Verrian, Avadel, Celon Pharma S.A., COMPASS, F. Hoffmann-La Roche Ltd, Hikma Pharmaceuticals PLC, NeuroRx, Inc., PharmaTher Inc., Mind Medicine, Inc., Cybin Corp., GABA Therapeutics, Inc., EmpathBio, DemeRx and Others.

The Growth of Psychedelic Drugs Market Driven by Growing recognition of the potential therapeutic benefits of psychedelic substances

The Psychedelic Drugs Market is being driven by various key factors. Firstly, there is a growing recognition of the potential therapeutic benefits of psychedelic substances. In recent years, there has been a renewed interest in studying these drugs for their ability to treat mental health conditions such as depression, anxiety, PTSD, and addiction. The positive outcomes observed in clinical trials and research studies have gained support and acceptance from the medical and scientific communities. Secondly, some governments and regulatory agencies in certain regions are open to exploring the medical use of psychedelic drugs. This changing regulatory landscape has created opportunities for companies to invest in research and development, leading to the expansion of the psychedelic drugs market. Additionally, there is a notable increase in public awareness and advocacy efforts for mental health, which has resulted in a growing demand for alternative and innovative treatments. As a result, many patients and healthcare providers are seeking options beyond traditional pharmaceuticals, contributing to the market growth of psychedelic drugs. The combination of these factors has led to a surge in investments, research activities, and the development of psychedelic-based treatments, ultimately driving the growth of the psychedelic drugs market. However, it's essential to consider that regulations, social perceptions, and ongoing research will continue to shape the future of this market.

Rising Awareness Towards Mental Health

Raising awareness about mental illness has become essential as it negatively affects people's ability to live a normal life. This includes educating the public about the various causes, related disorders, and treatment options available. Many organizations and companies are actively launching campaigns and initiatives to increase awareness, empowering patients to make informed decisions regarding their specific condition and symptoms. The use of advertisements and awareness campaigns has also played a role in promoting the recognition of psychedelic drugs as potential treatments for mental health conditions. Consequently, the growing awareness towards mental health is anticipated to be a driving force behind the expansion of the psychedelic drugs market.

North America Dominated the Psychedelic Drugs Market during the forecast period

In 2022, the North American region is poised to dominate the global psychedelic drugs market, driven by several factors. These include a surge in research and development activities in the psychedelic field, a growing emphasis on mental health treatment, and an increase in the prevalence of mental health disorders. The rising awareness surrounding the potential use of psychedelic drugs for treating mental health conditions is expected to further propel market growth. Moreover, the expansion of companies and the establishment of new psychedelic treatment centers are set to make significant contributions to the overall market growth in the region. The increasing incidence of mental disorders, coupled with focused awareness campaigns promoting psychedelic drug therapy for mental health issues, as well as the introduction of new psychedelic drug products, will likely lead to substantial market growth in North America during the forecast period.

On the other hand, Europe plays a crucial role in the increasing demand for psychedelic drugs, securing the second position globally. Among European countries, Germany stands out as a significant player in this market. The growing global population has also contributed to the escalating demand for hallucinogenic substances. Both private enterprises and government entities have invested significantly in new drug research and development, driving the European psychedelic drugs market to prominence. As the prevalence of mental illness continues to rise, individuals and governments alike are becoming more conscious of their health and well-being. This heightened awareness has led to a greater understanding of the potential benefits of psychedelic drugs in mental health treatment, further contributing to the significance of the European market in this domain.

The Psychedelic Drugs Market research report provides an in-depth overview of the industry including market segmentation by Source, Drug Type, Indication, Form, Route of Administration, End-user, Distribution Channel and Region. Analysis of the global market with special focus on high growth application in each vertical and fast-growing market segments. It includes detailed competitive landscape with identification of the key players with respect to each type of market, in-depth market share analysis with individual revenue, market shares, and top players rankings. Impact analysis of the market dynamics with factors currently driving and restraining the growth of the market, along with their impact in the short, medium, and long-term landscapes. Competitive intelligence from the company profiles, key player strategies, game-changing developments such as new product launch, collaborations, expansions, investment analysis, mergers and acquisitions.

Psychedelic Drugs Market is segmented by region and further by countries, Source, Drug Type, Indication, Form, Route of Administration, End-user, Distribution Channel and Region. Players, stakeholders, and other participants in the global Psychedelic Drugs Market will be able to gain a strong position as this report will surely benefit their marketing strategies. The market analysis focuses on revenue and forecast by region/countries and by application in terms of revenue forecast for the period 2023-2030.

Report further studies the market strategies of key players, recent development status, future plans and Psychedelic Drugs Market trends across the world. Also, it splits Psychedelic Drugs Market Segmentation by material, end-user and region to deep dive research and reveals company profile and prospects.

Major Classifications are as follows:

By Source

  • Natural Psychedelic Drugs
  • Synthetic Psychedelic Drugs

By Drug Type

  • Gamma Hydroxybutyric Acid (GHB)
  • Ketamine
  • Psilocybin
  • Lysergic Acid Diethylamide (LSD)
  • 3,4-MethylEnedioxyMethamphetamine
  • Others

By Indication

  • Depressive Disorders
  • Post-Traumatic Stress Disorders
  • Substance Abuse Disorders
  • Obsessive Compulsive Disorders
  • Alzheimer Dementia
  • Cluster Headaches
  • Others

By Form

  • Liquid
  • Capsules
  • Tablets

By Route of Administration

  • Oral Psychedelic Drugs
  • Injectable Psychedelic Drugs
  • Intramuscular
  • Subcutaneous
  • Intrathecal
  • Rectal Psychedelic Drugs
  • Nasal Psychedelic Drugs
  • Transdermal Psychedelic Drugs

By End-user

  • Hospital
  • Speciality Clinics
  • Homecare
  • Others

By Distribution Channel

  • Online Pharmacies
  • Hospital Pharmacies
  • Institutional Sales
  • Retail Sales
  • Retail pharmacies

By Region

  • North America
  • US
  • Canada
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Rest of Asia Pacific
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa
  • Rest of Middle East & Africa

Reason to Purchase this Psychedelic Drugs Market Report:

  • Determine prospective investment areas based on a detailed trend analysis of the global Psychedelic Drugs Market over the next years.
  • Gain an in-depth understanding of the underlying factors driving demand for different and Psychedelic Drugs Market segments in the top spending countries across the world and identify the opportunities offered by each of them.
  • Strengthen your understanding of the market in terms of demand drivers, industry trends, and the latest technological developments, among others.
  • Identify the major channels that are driving the global Psychedelic Drugs Market, providing a clear picture of future opportunities that can be tapped, resulting in revenue expansion.
  • Channelize resources by focusing on the ongoing programs that are being undertaken by the different countries within the global Psychedelic Drugs Market.
  • Make correct business decisions based on a thorough analysis of the total competitive landscape of the sector with detailed profiles of the top Psychedelic Drugs Market providers around the world which include information about their products, alliances, recent contract wins and financial analysis wherever available.


This product will be delivered within 3-5 business days.

Table of Contents

Executive Summary
  • Introduction
Key Takeaways
  • Report Description
  • Market Scope & Definition
  • Stakeholders
Research Methodology
  • Market size
  • Key data points from primary sources
  • Key data points from secondary sources
  • List of primary sources
  • List of secondary sources
Market Overview
  • Introduction
  • Industry Segmentation
  • Market Trends Analysis
  • Major Funding & Investments
Market Dynamics
  • Drivers
  • Restraints
  • Opportunities
  • Value Chain Analysis
Psychedelic Drugs Market, By Source
  • Introduction
  • Natural Psychedelic Drugs
  • Synthetic Psychedelic Drugs
Psychedelic Drugs Market, By Drug Type
  • Introduction
  • Gamma Hydroxybutyric Acid (GHB)
  • Ketamine
  • Psilocybin
  • Lysergic Acid Diethylamide (LSD)
  • 3,4-MethylEnedioxyMethamphetamine
  • Others
Psychedelic Drugs Market, By Indication
  • Introduction
  • Depressive Disorders
  • Post-Traumatic Stress Disorders
  • Substance Abuse Disorders
  • Obsessive Compulsive Disorders
  • Alzheimer Dementia
  • Cluster Headaches
  • Others
Psychedelic Drugs Market, By Form
  • Introduction
  • Liquid
  • Capsules
  • Tablets
Psychedelic Drugs Market, By Route of Administration
  • Introduction
  • Oral Psychedelic Drugs
  • Injectable Psychedelic Drugs
  • Intramuscular
  • Subcutaneous
  • Intrathecal
  • Rectal Psychedelic Drugs
  • Nasal Psychedelic Drugs
  • Transdermal Psychedelic Drugs
Psychedelic Drugs Market, By End-user
  • Introduction
  • Hospital
  • Speciality Clinics
  • Homecare
  • Others
Psychedelic Drugs Market, By Distribution Channel
  • Introduction
  • Online Pharmacies
  • Hospital Pharmacies
  • Institutional Sales
  • Retail Sales
  • Retail pharmacies
Psychedelic Drugs Market, By Geography
  • North America
  • U.S.
  • Canada
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Rest of Asia Pacific
  • Rest of the world (RoW)
  • Middle East
  • UAE
  • Saudi Arabia
  • Israel
  • Africa
  • South Africa
  • Rest of Africa
  • Competitive Landscapes
  • Introduction
  • Top Companies Ranking
  • Market Share Analysis
  • Competition Dashboard
  • Market Share Analysis (2022)
  • Emerging company case studies
Company Profiles
  • Jazz Pharmaceuticals, Inc.
  • Business Overview
  • Product Portfolio
  • Market Segments (Business Segment/Region)
  • Sales Footprint
  • Recent Developments
  • New Product Launch
  • Mergers & Acquisitions
  • Collaborations, Partnerships & Agreements
  • Rewards & Recognition
  • Janssen Pharmaceuticals
  • Business Overview
  • Product Portfolio
  • Market Segments (Business Segment/Region)
  • Sales Footprint
  • Recent Developments
  • New Product Launch
  • Mergers & Acquisitions
  • Collaborations, Partnerships & Agreements
  • Rewards & Recognition
  • Pfizer Inc.
  • Business Overview
  • Product Portfolio
  • Market Segments (Business Segment/Region)
  • Sales Footprint
  • Recent Developments
  • New Product Launch
  • Mergers & Acquisitions
  • Collaborations, Partnerships & Agreements
  • Rewards & Recognition
  • Pfizer Inc.
  • Business Overview
  • Product Portfolio
  • Market Segments (Business Segment/Region)
  • Sales Footprint
  • Recent Developments
  • New Product Launch
  • Mergers & Acquisitions
  • Collaborations, Partnerships & Agreements
  • Rewards & Recognition
  • Avadel
  • Business Overview
  • Product Portfolio
  • Market Segments (Business Segment/Region)
  • Sales Footprint
  • Recent Developments
  • New Product Launch
  • Mergers & Acquisitions
  • Collaborations, Partnerships & Agreements
  • Rewards & Recognition
  • Celon Pharma S.A.
  • Business Overview
  • Product Portfolio
  • Market Segments (Business Segment/Region)
  • Sales Footprint
  • Recent Developments
  • New Product Launch
  • Mergers & Acquisitions
  • Collaborations, Partnerships & Agreements
  • Rewards & Recognition
  • COMPASS
  • Business Overview
  • Product Portfolio
  • Market Segments (Business Segment/Region)
  • Sales Footprint
  • Recent Developments
  • New Product Launch
  • Mergers & Acquisitions
  • Collaborations, Partnerships & Agreements
  • Rewards & Recognition
  • F. Hoffmann-La Roche Ltd
  • Business Overview
  • Product Portfolio
  • Market Segments (Business Segment/Region)
  • Sales Footprint
  • Recent Developments
  • New Product Launch
  • Mergers & Acquisitions
  • Collaborations, Partnerships & Agreements
  • Rewards & Recognition
  • Hikma Pharmaceuticals PLC
  • Business Overview
  • Product Portfolio
  • Market Segments (Business Segment/Region)
  • Sales Footprint
  • Recent Developments
  • New Product Launch
  • Mergers & Acquisitions
  • Collaborations, Partnerships & Agreements
  • Rewards & Recognition
  • NeuroRx, Inc.
  • Business Overview
  • Product Portfolio
  • Market Segments (Business Segment/Region)
  • Sales Footprint
  • Recent Developments
  • New Product Launch
  • Mergers & Acquisitions
  • Collaborations, Partnerships & Agreements
  • Rewards & Recognition
  • PharmaTher Inc.
  • Business Overview
  • Product Portfolio
  • Market Segments (Business Segment/Region)
  • Sales Footprint
  • Recent Developments
  • New Product Launch
  • Mergers & Acquisitions
  • Collaborations, Partnerships & Agreements
  • Rewards & Recognition
  • Mind Medicine, Inc.
  • Business Overview
  • Product Portfolio
  • Market Segments (Business Segment/Region)
  • Sales Footprint
  • Recent Developments
  • New Product Launch
  • Mergers & Acquisitions
  • Collaborations, Partnerships & Agreements
  • Rewards & Recognition
  • Cybin Corp.
  • Business Overview
  • Product Portfolio
  • Market Segments (Business Segment/Region)
  • Sales Footprint
  • Recent Developments
  • New Product Launch
  • Mergers & Acquisitions
  • Collaborations, Partnerships & Agreements
  • Rewards & Recognition
  • GABA Therapeutics, Inc.
  • Business Overview
  • Product Portfolio
  • Market Segments (Business Segment/Region)
  • Sales Footprint
  • Recent Developments
  • New Product Launch
  • Mergers & Acquisitions
  • Collaborations, Partnerships & Agreements
  • Rewards & Recognition
  • EmpathBio
  • Business Overview
  • Product Portfolio
  • Market Segments (Business Segment/Region)
  • Sales Footprint
  • Recent Developments
  • New Product Launch
  • Mergers & Acquisitions
  • Collaborations, Partnerships & Agreements
  • Rewards & Recognition
  • DemeRx
  • Business Overview
  • Product Portfolio
  • Market Segments (Business Segment/Region)
  • Sales Footprint
  • Recent Developments
  • New Product Launch
  • Mergers & Acquisitions
  • Collaborations, Partnerships & Agreements
  • Rewards & Recognition

Companies Mentioned

  • Jazz Pharmaceuticals, Inc.
  • Janssen Pharmaceuticals
  • Pfizer Inc.
  • Pfizer Inc.
  • Avadel
  • Celon Pharma S.A.
  • COMPASS
  • F. Hoffmann-La Roche Ltd
  • Hikma Pharmaceuticals PLC
  • NeuroRx, Inc.
  • PharmaTher Inc.
  • Mind Medicine, Inc.
  • Cybin Corp.
  • GABA Therapeutics, Inc.
  • EmpathBio
  • DemeRx